News and Press Releases

Evotec and Pfizer collaborate to advance drug discovery in France

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases 11 July 2024, Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:...

Category: Drug Discovery
Posted: July 11, 2024

Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US

Pistoia Alliance Research Finds 77% of Researchers Not Using In Vitro Alternatives to Animal Testing, as it Launches Non-Animal Models Community

Alliance calls on experts to join its new collaborative community, seeking to overcome regulatory and data challenges preventing the replacement and reduction of animal testing 11 July 2024 -- Boston,...

Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: July 11, 2024

401 Edgewater Pl, Wakefield, Massachusetts, US

Pan Cancer T secures €4.25m in Seed Extension Round to advance next-generation T cell therapies

July 11 2024, Rotterdam, the Netherlands – Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25m Seed...

Category: Drug Delivery
Posted: July 11, 2024

Marconistraat 16 3029 AK, Rotterdam The Netherlands

Just – Evotec Biologics selected by US Department of Defence for Manufacturing Optimisation Programme

Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s manufacturing optimisation programme Manufacturing solution includes seamless integration of accelerated mAb drug development into...

Category: BioManufacturing
Posted: July 10, 2024

Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US

Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz

Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term...

Category: BioManufacturing, Biotechnology
Posted: July 10, 2024

Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US

Concr launches trial using digital twins for outcome prediction in breast cancer

10 July 2024, London United Kingdom – Concr announces that first patients have been recruited to the VISION trial, an observational clinical study evaluating Concr’s therapeutic response predictive algorithm defining...

Category: Biotechnology
Posted: July 10, 2024

11 Milbrook, Esher, KT10 9EJ, UK

Pascal Piedbois MD PhD joins One2Treat as chief medical officer to advance patient-centric innovation in clinical trial design and market access

One2Treat reflects patient priorities in a single multi-facet treatment assessment, reducing trial sample size and accelerating patient access to new treatments.  9 July 2024 -- Brussels, Belgium -- In this...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: July 10, 2024

Rue Emile Francqui, 1-1435 Mont-Saint-Guibert, Belgium

LSX Nordic Congress Event

LSX Nordic Congress gathers the founders and CEOs of innovative start-ups through to publicly listed healthcare giants, and everyone in between. It represents the breadth and depth of cutting-edge research...

Category:
Posted: July 9, 2024

Center Boulevard 5, Copenhagen, 2300 Denmark

SciRhom Secures €63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases

The upsized and oversubscribed Series A financing round will be used to drive the lead development programme toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2...

Category: Drug Discovery, Other, Pharmaceutical
Posted: July 9, 2024

Am Klopferspitz 19 82152 Planegg/Martinsried Germany

Microbiotica to Present Positive Update on Manufacturing Progress of its Live Biotherapeutic Products for Forthcoming Melanoma and Ulcerative Colitis Clinical Studies

9 July 2024, Cambridge United Kingdom – Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines called live biotherapeutic products (LBPs), announces that Adam Wilkinson, its vice...

Category: BioManufacturing, Drug Discovery
Posted: July 9, 2024

Microbiotica Limited Chesterford Research Park Little Chesterford Cambridge CB10 1XL UK

APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million 

Ligand also commits to invest up to USD 4 million in APEIRON spin-off, invIOs 8 July 2024, Vienna, Austria – APEIRON Biologics AG (“APEIRON”), a leading Austrian biotech company, today...

Category:
Posted: July 8, 2024

Campus-Vienna-Biocenter 5, 1030 Vienna, Austria

Epsilogen announces CTA approval for phase 1b trial of MOv18 IgE in platinum-resistant ovarian cancer

Phase 1b study expected to initiate in H2 2024 Previously reported phase 1 results showed MOv18 IgE to be safe and well-tolerated, with evidence of anti-tumour activity. 8 July 2024...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 8, 2024

Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH

Spur provides update on FLT201 and planned phase III clinical trial

8 July 2024 -- London, UK -- Syncona Ltd, a leading life science investor focused on creating, building and scaling global leaders in life science, notes that its portfolio company...

Category: Clinical Trials, Other, Pharmaceutical
Posted: July 8, 2024

2nd Floor, 8 Bloomsbury Street, London, WC1B 3SR

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors...

Category: BioManufacturing, Clinical Trials, Other
Posted: July 8, 2024

Myricx Bio Gridiron Building, 1 Pancras Square, King’s Cross, London, N1C 4AG

CSL Behring Announces First Two Patients Treated with HEMGENIX (etranacogene dezaparvovec) Gene Therapy for Haemophilia B in Europe

4 July 2024, Marburg, Germany– Global biotechnology leader CSL Behring (ASX: CSL) today announced that two haemophilia B patients were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec) at Haemophilia...

Category: Pharmaceutical
Posted: July 4, 2024

CSL Global Headquarters, 655 Elizabeth Street, Melbourne VIC 3000 Australia